This information is current as Infection and Clears Organ Parasites in Experimental Leishmania donovani Antimony-Resistant Macrophages Infected with To Increase the IL-12 / IL-10 Ratio in Imipramine Exploits Histone Deacetylase

[1]  Syamal Roy,et al.  Immunomodulatory effects of antileishmanial drugs. , 2013, The Journal of antimicrobial chemotherapy.

[2]  H. Abelaira,et al.  Ketamine and imipramine in the nucleus accumbens regulate histone deacetylation induced by maternal deprivation and are critical for associated behaviors , 2013, Behavioural Brain Research.

[3]  A. Fairlamb,et al.  Chronic exposure to arsenic in drinking water can lead to resistance to antimonial drugs in a mouse model of visceral leishmaniasis , 2013, Proceedings of the National Academy of Sciences.

[4]  J. Beijnen,et al.  Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  A. Bandyopadhyay,et al.  Post-kala-azar Dermal Leishmaniasis Developing in Miltefosine-Treated Visceral Leishmaniasis , 2013, Indian journal of dermatology.

[6]  S. Sundar,et al.  Antimony-resistant but not antimony-sensitive Leishmania donovani up-regulates host IL-10 to overexpress multidrug-resistant protein 1 , 2013, Proceedings of the National Academy of Sciences.

[7]  S. Plevy,et al.  IL-10 Regulates Il12b Expression via Histone Deacetylation: Implications for Intestinal Macrophage Homeostasis , 2012, The Journal of Immunology.

[8]  S. Norval,et al.  The Anti-Trypanosome Drug Fexinidazole Shows Potential for Treating Visceral Leishmaniasis , 2012, Science Translational Medicine.

[9]  M. Quail,et al.  Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance. , 2011, Genome research.

[10]  S. Sundar,et al.  Characterisation of antimony-resistant Leishmania donovani isolates: biochemical and biophysical studies and interaction with host cells. , 2011, International journal for parasitology.

[11]  A. Fairlamb,et al.  Visceral Leishmaniasis and Arsenic: An Ancient Poison Contributing to Antimonial Treatment Failure in the Indian Subcontinent? , 2011, PLoS neglected tropical diseases.

[12]  Kelly Chibale,et al.  Drug repositioning in the treatment of malaria and TB. , 2011, Future medicinal chemistry.

[13]  Michael P Barrett,et al.  Development of novel drugs for human African trypanosomiasis. , 2011, Future microbiology.

[14]  Syamal Roy,et al.  Use of Antimony in the Treatment of Leishmaniasis: Current Status and Future Directions , 2011, Molecular biology international.

[15]  J. M. Pérez-Victoria,et al.  Sitamaquine Overcomes ABC-Mediated Resistance to Miltefosine and Antimony in Leishmania , 2011, Antimicrobial Agents and Chemotherapy.

[16]  S. Sundar,et al.  Unusual Case of Resistance to Amphotericin B in Visceral Leishmaniasis in a Region in India Where Leishmaniasis Is Not Endemic , 2011, Journal of Clinical Microbiology.

[17]  D. van Soolingen,et al.  The Antipsychotic Thioridazine Shows Promising Therapeutic Activity in a Mouse Model of Multidrug-Resistant Tuberculosis , 2010, PloS one.

[18]  S. Sundar,et al.  Drug Resistance in Leishmaniasis , 2010, Journal of global infectious diseases.

[19]  Syamal Roy,et al.  Leishmania donovani Isolates with Antimony-Resistant but Not -Sensitive Phenotype Inhibit Sodium Antimony Gluconate-Induced Dendritic Cell Activation , 2010, PLoS pathogens.

[20]  W. Coward,et al.  Repression of IP-10 by Interactions between Histone Deacetylation and Hypermethylation in Idiopathic Pulmonary Fibrosis , 2010, Molecular and Cellular Biology.

[21]  S. Bandyopadhyay,et al.  Innate immune defense in visceral leishmaniasis: cytokine mediated protective role by allogeneic effector cell. , 2010, Vaccine.

[22]  O. Kaneko,et al.  Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient. , 2009, The American journal of tropical medicine and hygiene.

[23]  D. Singh,et al.  Development of Post–Kala-Azar Dermal Leishmaniasis (PKDL) in Miltefosine-Treated Visceral Leishmaniasis , 2009 .

[24]  Thomas Dick,et al.  The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis , 2008, Proceedings of the National Academy of Sciences.

[25]  S. K. Choudhuri,et al.  Inhibition of ABC Transporters Abolishes Antimony Resistance in Leishmania Infection , 2007, Antimicrobial Agents and Chemotherapy.

[26]  Nihal Ahmad,et al.  Dose translation from animal to human studies revisited , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  Syamal Roy,et al.  HLA class I-restricted T cell epitopes of the kinetoplastid membrane protein-11 presented by Leishmania donovani-infected human macrophages. , 2007, The Journal of infectious diseases.

[28]  S. K. Choudhuri,et al.  Sodium Antimony Gluconate Induces Generation of Reactive Oxygen Species and Nitric Oxide via Phosphoinositide 3-Kinase and Mitogen-Activated Protein Kinase Activation in Leishmania donovani-Infected Macrophages , 2006, Antimicrobial Agents and Chemotherapy.

[29]  M. Kaplan,et al.  Interleukin (IL)-4 inhibits IL-10 to promote IL-12 production by dendritic cells , 2005, The Journal of experimental medicine.

[30]  Syamal Roy,et al.  Kinetoplastid Membrane Protein-11 DNA Vaccination Induces Complete Protection against Both Pentavalent Antimonial-Sensitive and -Resistant Strains of Leishmania donovani That Correlates with Inducible Nitric Oxide Synthase Activity and IL-4 Generation: Evidence for Mixed Th1- and Th2-Like Responses , 2005, The Journal of Immunology.

[31]  S. Smale,et al.  Interleukin-10 Inhibits Interleukin-12 p40 Gene Transcription by Targeting a Late Event in the Activation Pathway , 2004, Molecular and Cellular Biology.

[32]  M. Maes,et al.  Stimulatory effect of antidepressants on the production of IL-6. , 2004, International immunopharmacology.

[33]  B. Dasgupta,et al.  Infection of Human Mononuclear Phagocytes and Macrophage‐Like THP1 Cells with Leishmania donovani Results in Modulation of Expression of a Subset of Chemokines and a Chemokine Receptor , 2003, Scandinavian journal of immunology.

[34]  R. Coffman,et al.  Interleukin-10 (IL-10) in Experimental Visceral Leishmaniasis and IL-10 Receptor Blockade as Immunotherapy , 2002, Infection and Immunity.

[35]  Y. Belkaid,et al.  The Role of Interleukin (IL)-10 in the Persistence of Leishmania major in the Skin after Healing and the Therapeutic Potential of Anti–IL-10 Receptor Antibody for Sterile Cure , 2001, The Journal of experimental medicine.

[36]  S. Sundar.  Drug resistance in Indian visceral leishmaniasis , 2001, Tropical medicine & international health : TM & IH.

[37]  S. Sundar,et al.  Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  S. Sundar,et al.  Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. , 1999, The Journal of infectious diseases.

[39]  P. Sen,et al.  Immunoprophylaxis and immunotherapy against experimental visceral leishmaniasis. , 1999, Vaccine.

[40]  M. Atchison,et al.  Transcription Factor Pip Can Enhance DNA Binding by E47, Leading to Transcriptional Synergy Involving Multiple Protein Domains , 1998, Molecular and Cellular Biology.

[41]  E. D. de Kloet,et al.  Differential regulation of interleukin-10 (IL-10) and IL-12 by glucocorticoids in vitro. , 1998, Blood.

[42]  W. Johnson,et al.  Interleukin-12 restores interferon-gamma production and cytotoxic responses in visceral leishmaniasis. , 1996, The Journal of infectious diseases.

[43]  L. Demer,et al.  Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. , 1996, The Journal of clinical investigation.

[44]  G. Trinchieri,et al.  IL-12 enhances Th1-type responses in human Leishmania donovani infections. , 1995, Journal of immunology.

[45]  J. Becker,et al.  Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. , 1995, Melanoma research.

[46]  Mohamed,et al.  Interleukin 10 production correlates with pathology in human Leishmania donovani infections. , 1993, The Journal of clinical investigation.

[47]  A. Gepstein,et al.  Tricyclic drugs reduce proton motive force in Leishmania donovani promastigotes. , 1990, Biochemical pharmacology.

[48]  K. E. Newhouse.  Goodman and Gilman's The Pharmacological Basis of Therapeutics , 1986, The Yale Journal of Biology and Medicine.

[49]  D. Klein,et al.  The safety of a single daily dose schedule for imipramine. , 1971, The American journal of psychiatry.

[50]  J. Gerrard,et al.  Nocturnal enuresis: comparison of the effect of imipramine and dietary restriction on bladder capacity. , 1969, Canadian Medical Association journal.

[51]  References Subscriptions Permissions Email Alerts The Hamster as a Model of Human Visceral Leishmaniasis: Progressive Disease and Impaired Generation of Nitric Oxide in the Face of a Prominent Th1-Like Cytokine Response , 2013 .

[52]  P. Atadja,et al.  The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance , 2009, Nature Immunology.

[53]  É. Rosenthal,et al.  [Visceral leishmaniases]. , 2004, La Revue du praticien.

[54]  P. Doyle,et al.  Isolation of lipophosphoglycans from Leishmania donovani amastigotes. , 1996, Archives of biochemistry and biophysics.

[55]  Thomas R. Tice,et al.  Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the peyer's patches , 1990 .